Santhera's Shareholders Approve all Board Proposals at Annual Shareholders' Meeting
(Thomson Reuters ONE) -
Santhera Pharmaceuticals Holding AG /
Santhera's Shareholders Approve all Board Proposals at Annual Shareholders'
Meeting
. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
Liestal, Switzerland, May 11, 2016 - Santhera Pharmaceuticals (SIX: SANN)
announces that a large majority of shareholders approved all proposals by the
Board of Directors at the Annual Shareholders' Meeting (ASM) today.
Participating shareholders represented a total of 3'211'953 shares or 51.2% of
the share capital with voting power.
"The results of today's ASM are a strong vote of confidence in our strategy and
achievements and I thank our shareholders for their consent and support," said
Martin Gertsch, Chairman of the Board of Directors. "Indeed, 2015 was an
exceptionally successful year for Santhera with many milestones. After the
European Commission granted marketing approval for Raxone(®) for the treatment
of Leber's hereditary optic neuropathy (LHON), we are at present advancing the
commercial roll-out across Europe. The regulatory filing for the second
indication Duchenne muscular dystrophy (DMD) in Europe will follow very soon and
we have now requested a meeting with the FDA to discuss the filing also in the
US. Financially, we closed 2015 with a positive result and our strong cash
position from successful financings allows us to advance our development
programs and support our transition to a fully integrated specialty
pharmaceutical company.
Approval of the 2015 Annual Report, result appropriation and reallocation of
reserves
The shareholders endorsed the Annual Report, the annual financial statements and
the consolidated financial statements for 2015, the appropriation of the net
result of CHF -2,963,843 to new account as well as the reallocation of reserves
from capital contribution to free reserves. Furthermore, the shareholders
granted discharge to the members of the Board of Directors and Executive
Management for the financial year 2015.
Improved capital structure supports strategic flexibility and expansion of the
organization
The shareholders approved the increase and extension of the authorized capital
and the increase of the conditional capital for employee participation. With
their consent, the shareholders strengthen the financial flexibility of the
Company, particularly in view of upcoming regulatory submissions, additional
clinical development efforts, continuation of commercial roll-out and the
related build-up and expansion of the organization with qualified staff.
Remuneration for Board of Directors and Executive Management approved
In a consultative vote, the shareholders endorsed the Compensation Report 2015.
The shareholders consented to the total annual compensation amounts for members
of the Board of Directors up to the Annual Shareholder's Meeting 2017. For
Executive Management, the shareholders approved the alignment of the
compensation period of the fixed compensation to the financial year of the
Company (January 1 to December 31) and gave their consent to the fixed
compensation for the financial years 2016 and 2017. Subsequently, they also
approved the change of the voting procedure on the variable compensation to a
retrospective approval which will apply first time for the business year 2016.
Re-election of members of the Board of Directors
Shareholders confirmed Martin Gertsch and Jürg Ambühl as members of the Board of
Directors and the Compensation Committee. Furthermore, Martin Gertsch was re-
elected as Chairman of the Board for another term of one year.
Shareholders also supported the appointment of Ernst & Young Ltd. as auditors
for the financial year 2016 and elected Dr. Balthasar Settelen, Basel, as
independent proxy until the close of the Annual Shareholders' Meeting 2017.
Details on the agenda items
The proposals and explanations about the agenda items are available on the
Company's website at Investors and Media/Investor toolbox/Shareholder Meetings.
From end of this week, the protocol of the Annual Shareholder's Meeting will
also be available.
New website
Santhera has today launched its new www.santhera.com website. The new website
has been de-signed to reflect the Company's business focus and market strategies
and supports the positioning of Santhera as a leader in developing medicines to
meet the needs of patients living with mitochondrial disorders and other rare
diseases.
About Santhera
Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company
focused on the development and commercialization of innovative pharmaceutical
products for the treatment of orphan mitochondrial and neuromuscular diseases.
Santhera's lead product Raxone(®) is authorized in the European Union for the
treatment of Leber's hereditary optic neuropathy (LHON). Santhera develops
Raxone(®) in two additional indications, Duchenne muscular dystrophy (DMD) and
primary progressive multiple sclerosis (PPMS), and omigapil for congenital
muscular dystrophy (CMD), all areas of high unmet medical need. For further
information, please visit the Company's website www.santhera.com.
Raxone(®) and Catena(®) are trademarks of Santhera Pharmaceuticals.
For further information, contact:
Thomas Meier, PhD, Chief Executive Officer Christoph Rentsch, Chief
Financial Officer
Phone +41 61 906 89 64 Phone
+41 61 906 89 65
thomas.meier(at)santhera.com
christoph.rentsch(at)santhera.com
US investor contact US Public Relations
contact
Hans Vitzthum, LifeSci Advisors, LLC Deanne Eagle, Planet
Communications
Phone +1 212 915 2568 Phone
+1 917 837 5866
hans(at)lifesciadvisors.com
deanne(at)planetcommunications.nyc
Disclaimer / Forward-looking statements
This communication does not constitute an offer or invitation to subscribe for
or purchase any securities of Santhera Pharmaceuticals Holding AG. This
publication may contain certain forward-looking statements concerning the
Company and its business. Such statements involve certain risks, uncertainties
and other factors which could cause the actual results, financial condition,
performance or achievements of the Company to be materially different from those
expressed or implied by such statements. Readers should therefore not place
undue reliance on these statements, particularly not in connection with any
contract or investment decision. The Company disclaims any obligation to update
these forward-looking statements.
# # #
News release Annual Shareholder Meeting 2016:
http://hugin.info/137261/R/2011706/744911.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Santhera Pharmaceuticals Holding AG via GlobeNewswire
[HUG#2011706]
Unternehmensinformation / Kurzprofil:
Datum: 11.05.2016 - 12:51 Uhr
Sprache: Deutsch
News-ID 470332
Anzahl Zeichen: 8253
contact information:
Town:
Liestal
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 202 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Santhera's Shareholders Approve all Board Proposals at Annual Shareholders' Meeting"
steht unter der journalistisch-redaktionellen Verantwortung von
Santhera Pharmaceuticals Holding AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
